On 10 December 2025, Amplex AB (“Amplex” or the “Bidder”) announced a public offer to the holders of shares and warrants in ADDvise Group AB (publ) (“ADDvise” or the “Company”) to transfer all their shares and warrants in the Company to Amplex (the “Offer”). To provide shareholders and warrant holders in ADDvise with the necessary … Read more
ADDvise Group AB (publ) (the “Company” or “ADDvise”) announces that the Company has received the bondholders’ approval of the proposed amendments in the written procedure under the terms and conditions of the Company’s outstanding bonds 2025/2028 with ISIN SE0025011885 (the “Bonds”) that was initiated on 2 January 2026 (the “Written Procedure”). The Written Procedure was … Read more
ADDvise Group AB (publ) (the “Company” or “ADDvise”) has instructed the agent under the Company’s outstanding bonds 2025/2028 with ISIN SE0025011885 (the “Bonds”) to initiate a written procedure in which the Company requests that the bondholders approve certain amendments to the terms and conditions of the Bonds (the “Written Procedure”). The proposed amendments in the … Read more
Amplex AB (“Amplex”) has today announced a public offer to the shareholders and warrant holders of ADDvise Group AB (publ) (“ADDvise”) to transfer all shares and warrants in ADDvise to Amplex at a price of SEK 1.65 in cash for each class A and class B share and SEK 0.49 in cash for each warrant … Read more
ADDvise Group’s subsidiary MRC Systems has received an order from IPS. IPS are a global engineering firm that delivers complex projects within life science. The order is worth approximately USD 2.3 million. The order involves design, paneling, and installation of a cleanroom and associated accessories for a new pharmaceutical manufacturing facility located in the United … Read more
Strengthened profitability and cash flow despite a quarter with macro headwinds. In the third quarter, organic sales decreased by 4.8% in constant currency, but the year-to-date growth remains positive. The work on operational efficiency is having an effect and EBITA increased by SEK 1.0 million while the EBITA margin amounted to 15.5% (13.7%). Cash flow … Read more
In the second quarter of 2025, organic sales adjusted for currency effects increased, driven by steady demand for laboratory equipment and rental of equipment for clinical studies. Operating cash flow improved in the quarter, and EBITA was in line with last year with a stronger margin. Through the new capital structure, ADDvise’s annual interest expenses … Read more
ADDvise Group AB (publ) (“ADDvise” or the “Company”) has mandated Nordea Bank Abp to arrange a series of credit investor meetings commencing on 14 May 2025, to explore the possibility of issuing senior unsecured floating rate bonds with an expected volume of SEK 800 million within a framework of SEK 1,600 million and with a … Read more
In the first quarter of 2025, net revenue increased organically with continued good profitability, which shows stable demand in medical technology and laboratory solutions. Cash flow from operating activities was strong, driven by improved working capital while EBITA, the company’s new main profit measure, decreased compared to the same quarter last year. Through increased operational … Read more
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES), AUSTRALIA, CANADA, BELARUS, HONG KONG, JAPAN, NEW ZEALAND AND RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, … Read more